Bristol Myers Squibb acquires Karuna Therapeutics
Bristol Myers Squibb and Karuna Therapeutics, Inc. recently announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired. The transaction was unanimously approved […]
